Optimind Pharma Corp.
OMND
CNSX
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 81.70K | 81.90K | 72.40K | 91.00K | 102.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 81.70K | 81.90K | 72.40K | 91.00K | 102.00K |
| Cost of Revenue | 28.40K | 30.20K | 37.10K | 47.80K | 73.90K |
| Gross Profit | 53.30K | 51.70K | 35.40K | 43.40K | 28.40K |
| SG&A Expenses | 285.70K | 344.30K | 378.30K | 497.80K | 476.00K |
| Depreciation & Amortization | 0.00 | 3.70K | 9.30K | 14.80K | 22.90K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 314.00K | 378.20K | 424.70K | 648.80K | 661.10K |
| Operating Income | -232.30K | -296.20K | -352.20K | -557.70K | -559.00K |
| Income Before Tax | -670.40K | -740.30K | -817.70K | -1.04M | -1.99M |
| Income Tax Expenses | -6.50K | -6.50K | -6.50K | -6.50K | -4.30K |
| Earnings from Continuing Operations | -0.66 | -0.73 | -0.81 | -1.04 | -1.98 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -663.90K | -733.80K | -811.20K | -1.04M | -1.98M |
| EBIT | -232.30K | -296.20K | -352.20K | -557.70K | -559.00K |
| EBITDA | -98.10K | -164.40K | -274.60K | -547.50K | -548.80K |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 439.88M | 428.18M | 417.00M | 398.07M | 391.61M |
| Average Diluted Shares Outstanding | 439.88M | 428.18M | 417.00M | 398.07M | 391.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
